Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study
Abstract Background Weekly paclitaxel + ramucirumab (wPTX + RAM) therapy is recommended as the standard second-line chemotherapy regimen for unresectable advanced/recurrent gastric cancer (GC) or esophagogastric junction cancer. Recent subgroup analysis of the RAINBOW trial revealed a higher frequen...
Main Authors: | Katsuhiko Nara, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, Hiroshi Suzuki |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-11469-y |
Similar Items
-
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
by: Keita Miura, et al.
Published: (2024-02-01) -
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01) -
How I treat febrile neutropenia
by: Marcio Nucci
Published: (2021-02-01) -
Prediction of esophagogastric varices associated with oxaliplatin administration
by: Yosuke Satta, et al.
Published: (2021-11-01) -
La neutropenia
by: Efraín Pulla Cadmilema, et al.
Published: (2023-08-01)